Fabio Rugani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fabio Rugani has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Icro Maremmani
Faculty of Medicine, Saint Camillus International University of Health and Medical Sciences (UniCamillus), Via di Sant’Alessandro 8, 00131 Rome, Italy
4 shared publications - Luca Rovai
Department of Psychiatry, North-Western Tuscany Local Health Unit, Apuan Zone, Massa, Italy
4 shared publications - Liliana Dell'Osso
Department of Psychiatry, Neurobiology, Pharmacology, Biotechnology, University of Pisa, Italy
3 shared publications - Matteo Pacini
G. De Lisio Institute of Behavioral Sciences, 56100 Pisa, Italy
3 shared publications - Silvia Bacciardi
Vincent P. Dole Dual Diagnosis Unit, Santa Chiara University Hospital, Department of Neurosciences, University of Pisa, Pisa 56100, Italy
3 shared publications - Joseph Deltito
Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS), Pietrasanta, Lucca 55045, Italy
2 shared publications
Latest Publications
- Open Access
- 27 June 2012
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 9 (7) , 2283-2292
Symptomatological Features of Patients with and without Ecstasy Use during Their First Psychotic Episode
Background: Ecstasy use is generally chosen by adolescents and young adults for its entactogenic properties (the production of feelings of empathy, love, and emotional closeness to others.) Despite this desired and frequently realized outcome, Ecstasy use has often resulted in the genesis of psychotic symptoms and aggressive behaviors, particularly after chronic and/or intensive use. Methods: To explore the negative consequences of Ecstasy use and to examine the aggressive nature oftentimes seen in many Ecstasy users we employed a case-control study model. We compared, by means of validated psychometric tests, the psychopathological symptoms (BPRS), the aggressiveness (OAS) and the social adjustment (DSM-GAF) of psychotic patients with (n = 23) and without (n = 46) recent user of Ecstasy, during their first psychotic episode and hospitalization. All 23 Ecstasy users were Ecstasy users only. Results: Almost all of the psychotic symptoms were of similar severity in both groups. Blunted affect was milder in users than in non-users, whereas hostility and aggressive behavior was significantly more severe in users than in non-users. Conclusions: psychosis with a high level of aggressiveness and violence constitutes an important ‘side-effect’ that surely runs counter to the expected entactogenic action of Ecstasy. At a patient psycho-educational level, this study suggests that the use of Ecstasy may be counterproductive with respect to user expectations.
- 27 June 2012
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 9 (7) , 2283-2292
Open AccessSymptomatological Features of Patients with and without Ecstasy Use during Their First Psychotic Episode
Background: Ecstasy use is generally chosen by adolescents and young adults for its entactogenic properties (the production of feelings of empathy, love, and emotional closeness to others.) Despite this desired and frequently realized outcome, Ecstasy use has often resulted in the genesis of psychotic symptoms and aggressive behaviors, particularly after chronic and/or intensive use. Methods: To explore the negative consequences of Ecstasy use and to examine the aggressive nature oftentimes seen in many Ecstasy users we employed a case-control study model. We compared, by means of validated psychometric tests, the psychopathological symptoms (BPRS), the aggressiveness (OAS) and the social adjustment (DSM-GAF) of psychotic patients with (n = 23) and without (n = 46) recent user of Ecstasy, during their first psychotic episode and hospitalization. All 23 Ecstasy users were Ecstasy users only. Results: Almost all of the psychotic symptoms were of similar severity in both groups. Blunted affect was milder in users than in non-users, whereas hostility and aggressive behavior was significantly more severe in users than in non-users. Conclusions: psychosis with a high level of aggressiveness and violence constitutes an important ‘side-effect’ that surely runs counter to the expected entactogenic action of Ecstasy. At a patient psycho-educational level, this study suggests that the use of Ecstasy may be counterproductive with respect to user expectations.
- Open Access
- 1 January 2012
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 11 (1) , 23
Clinical presentations of substance abuse in bipolar heroin addicts at time of treatment entry
Studies on the ‘self-medication hypothesis’ have focused on substance abuse as an attempt to alleviate emotional suffering.
- 1 January 2012
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 11 (1) , 23
Open AccessClinical presentations of substance abuse in bipolar heroin addicts at time of treatment entry
Studies on the ‘self-medication hypothesis’ have focused on substance abuse as an attempt to alleviate emotional suffering.
- Open Access
- 1 January 2011
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 10 (1) , 17
Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?
The idea that the impact of opioid agonist treatment is influenced by the psychopathological profile of heroin addicts has not yet been investigated, and is based on the concept of a specific therapeutic action displayed by opioid agents on psychopathological symptoms. In the present report we compared the effects of buprenorphine and methadone on the psychopathological symptoms of 213 patients (106 on buprenorphine and 107 on methadone) in a follow-up study lasting 12 months.
- 1 January 2011
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 10 (1) , 17
Open AccessDo methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?
The idea that the impact of opioid agonist treatment is influenced by the psychopathological profile of heroin addicts has not yet been investigated, and is based on the concept of a specific therapeutic action displayed by opioid agents on psychopathological symptoms. In the present report we compared the effects of buprenorphine and methadone on the psychopathological symptoms of 213 patients (106 on buprenorphine and 107 on methadone) in a follow-up study lasting 12 months.